Late phases expertise
Accellena's first clinical trial in 2015 was a proof-of-concept trial of an antitumor drug conducted in the USA, Europe and the CIS. By 2018, the company conducted more than 15 clinical trials, and by mid-2022, we took part in more than 70 clinical trial projects.
More than 25 of these were late phase clinical trials at various stages, including 15 completed by today.
The company has acquired the greatest experience in late phase research in the following areas: research on vaccines, infectious diseases, oncology, neurology, gastroenterology and surgery.
The company's experience is not limited to clinical trials. Since 2015, Accellena has been involved in major case-control epidemiological studies in the field of infectious diseases. We has successfully conducted a study of medical nutrition, cellular biomedical products (CAR-T therapy), and are actively involved in the study of the safety and efficacy of medical devices, both diagnostic and used for treatment, including life-threatening conditions in CPR units.